Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of subcutaneous tocilizumab weekly vs every 2 weeks in RA with inadequate response to Q2W dosing
jRCT2080222455Phase 3
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Apr 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tocilizumab in rheumatoid arthritis (RA) (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT2080222455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222455.